Concepedia

Weixiu Luo

WL

Statistics

Publications

21

Citations

3.2K

H-Index

16

Active since

2007

Affiliations

Dana-Farber Cancer Institute(Current)

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

International Breast Cancer Study Group

Harvard University

Weixiu Luo is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and chemotherapy.

Publications per year

2007–2020

21

Publications

21

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Olivia Pagani, Meredith M. Regan, Barbara Walley et al. · New England Journal of Medicine · 2014 · 747 citations · Full text

Medicine, Gynecology, Oncology +17

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 584 citations · Full text

Medicine, Gynecology, Oncology +16

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 262 citations

Medicine, Oncology, Pharmacology +13

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

Joyce F. Liu, Christina I. Herold, Kathryn P. Gray et al. · JAMA Oncology · 2019 · 227 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu et al. · Journal of Clinical Oncology · 2019 · 218 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 21